BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29271113)

  • 1. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy.
    Huang NS; Si J; Yang BL; Quan CL; Chen JJ; Wu J
    Cancer Med; 2018 Jan; 7(1):56-63. PubMed ID: 29271113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Influence of Hospital and Surgeon Factors on the Prevalence of Axillary Lymph Node Evaluation in Ductal Carcinoma In Situ.
    Coromilas EJ; Wright JD; Huang Y; Feldman S; Neugut AI; Chen L; Hershman DL
    JAMA Oncol; 2015 Jun; 1(3):323-32. PubMed ID: 26181180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Surgical Trends for Axillary Lymph Node Management in Patients with Ductal Carcinoma In Situ Using the NSQIP Database: Are We Following National Guidelines?
    Pyfer BJ; Jonczyk M; Jean J; Graham RA; Chen L; Chatterjee A
    Ann Surg Oncol; 2020 Sep; 27(9):3448-3455. PubMed ID: 32232706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
    Ramzi S; Najeeb E; Coulthard J; Jenkins S
    Breast Cancer Res Treat; 2020 Jul; 182(1):47-54. PubMed ID: 32430678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Necessity of sentinel lymph node biopsy in ductal carcinoma in situ patients: a retrospective analysis.
    Shin YD; Lee HM; Choi YJ
    BMC Surg; 2021 Mar; 21(1):159. PubMed ID: 33752671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A single-center retrospective study on axillary evaluation in 1 557 breast ductal carcinoma in situ patients between 2006 and 2016].
    Si J; Quan CL; Mo M; Guo R; Su YH; Yang BL; Chen JJ; Shao ZM; Wu J
    Zhonghua Wai Ke Za Zhi; 2019 Sep; 57(9):681-685. PubMed ID: 31474060
    [No Abstract]   [Full Text] [Related]  

  • 7. A N0 Predicting Model for Sentinel Lymph Node Biopsy Omission in Early Breast Cancer Upstaged From Ductal Carcinoma in Situ.
    Yoo TK; Kim SJ; Lee J; Lee SB; Lee SJ; Park HY; Park HK; Chae BJ; Eom YH; Kim HS; Song BJ
    Clin Breast Cancer; 2020 Jun; 20(3):e281-e289. PubMed ID: 32147404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
    Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
    J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?
    Sorrentino L; Sartani A; Bossi D; Amadori R; Nebuloni M; Truffi M; Bonzini M; Riggio E; Foschi D; Corsi F
    Breast J; 2018 May; 24(3):325-333. PubMed ID: 29024241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term morbidity of patients with early breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection.
    Schulze T; Mucke J; Markwardt J; Schlag PM; Bembenek A
    J Surg Oncol; 2006 Feb; 93(2):109-19. PubMed ID: 16425290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy.
    Intra M; Trifirò G; Viale G; Rotmensz N; Gentilini OD; Soteldo J; Galimberti V; Veronesi P; Luini A; Paganelli G; Veronesi U
    Ann Surg Oncol; 2005 Nov; 12(11):895-9. PubMed ID: 16195833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is Sentinel Lymph Node Biopsy Necessary for Ductal Carcinoma In Situ Patients Undergoing Mastectomy?
    Miller-Ocuin JL; Howard-McNatt M; Levine EA; Chiba A
    Am Surg; 2020 Aug; 86(8):955-957. PubMed ID: 32862671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The State of Surgical Axillary Management and Adjuvant Radiotherapy for Early-stage Invasive Breast Cancer in the Modern Era.
    Mann JM; Wu X; Christos P; Nagar H
    Clin Breast Cancer; 2018 Aug; 18(4):e477-e493. PubMed ID: 29031423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy.
    van Roozendaal LM; Goorts B; Klinkert M; Keymeulen KBMI; De Vries B; Strobbe LJA; Wauters CAP; van Riet YE; Degreef E; Rutgers EJT; Wesseling J; Smidt ML
    Breast Cancer Res Treat; 2016 Apr; 156(3):517-525. PubMed ID: 27083179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy.
    Park HS; Park S; Cho J; Park JM; Kim SI; Park BW
    J Surg Oncol; 2013 Mar; 107(4):388-92. PubMed ID: 23007901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates.
    Bae SJ; Kook Y; Jang JS; Baek SH; Moon S; Kim JH; Lee SE; Kim MJ; Ahn SG; Jeong J
    Breast Cancer Res; 2024 Apr; 26(1):65. PubMed ID: 38609935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of axillary positive sentinel lymph node biopsy in extended ductal carcinoma in situ treated by simple mastectomy at once.
    Hotton J; Salleron J; Rauch P; Buhler J; Pierret M; Baumard F; Leufflen L; Marchal F
    J Gynecol Obstet Hum Reprod; 2020 Mar; 49(3):101641. PubMed ID: 31562936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands.
    van Steenbergen LN; Voogd AC; Roukema JA; Louwman WJ; Duijm LE; Coebergh JW; van de Poll-Franse LV
    Breast; 2014 Feb; 23(1):63-8. PubMed ID: 24291376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy is not necessary in patients diagnosed with ductal carcinoma in situ of the breast by stereotactic vacuum-assisted biopsy.
    Kotani H; Yoshimura A; Adachi Y; Ishiguro J; Hisada T; Ichikawa M; Gondou N; Hattori M; Kondou N; Sawaki M; Fujita T; Iwata H
    Breast Cancer; 2016 Mar; 23(2):190-4. PubMed ID: 24989112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.
    Yi M; Giordano SH; Meric-Bernstam F; Mittendorf EA; Kuerer HM; Hwang RF; Bedrosian I; Rourke L; Hunt KK
    Ann Surg Oncol; 2010 Oct; 17 Suppl 3(0 3):343-51. PubMed ID: 20853057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.